Impact of Surgical Management for Relapse After Conversion Hepatectomy for Initially Unresectable Colorectal Liver Metastasis

Fudan University255 enrolled

Overview

For patients with initially unresectable colorectal liver metastasis (IU-CRLM) receiving effective conversion therapy, disease relapse after conversion hepatectomy is common due to the extensive tumor load. Yet, few studies have focused on the assessment and management of relapse after conversion hepatectomy for IU-CRLM. This study aimed to investigate the impact of surgical management for relapse after conversion hepatectomy in IU-CRLM.

Study Type

OBSERVATIONAL

Enrollment

255

Conditions

Colorectal Cancer Liver Metastases

Interventions

Repeat Liver SurgeryPROCEDURE

repeat liver surgery included not only hepatectomy, but also ablative treatment, including radiofrequency ablation (RFA) and microwave ablation (MWA)

Non-Repeat Liver SurgeryPROCEDURE

Systemic palliative chemotherapy

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * initially unresectable colorectal liver metastasis (IU-CRLM) * received conversion therapy * underwent conversion hepatectomy Exclusion Criteria: * the histologic type of CRLM was not called adenocarcinoma * uncontrollable extrahepatic metastases, such as peritoneal, bone, brain metastasis * history of previous hepatectomy * the primary tumor was not resected or palliative resection * R1 or R2 liver resection

Outcomes

Primary Outcomes

overall survival

Overall survival after the first resection of liver metastatic lesions

Time frame: 5 years

Secondary Outcomes

first relapse free survival

relapse free survival after the first resection of liver metastatic lesions

Time frame: 5 years

second relapse free survival

relapse free survival after the repeat liver surgery of liver metastatic lesions

Time frame: 5 years

Severe complication rate after resection of primary and metastatic lesions

Grade of III-V complication rate according to Clavien-Dindo

Time frame: 30 days after surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.